Exchange: NASDAQ·Updated 09:09 AM EDT

INSM News

News
all
press releases
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire BRIDGEWATER, N.J., Sept. 4, 2026 BRIDGEWATER, N.J., Sept. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global...
PR Newswire
More News
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026 Insmed to Present Data Across Its Respiratory Portfolio, Including New...
PR Newswire
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.
Zacks
If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today
Insmed (NASDAQ:INSM) has outperformed the market over the past 10 years by 10.74% on an annualized basis producing an average annual return of 24.29%. Currently, Insmed has a market capitalization of $26.34 billion.read more...
Benzinga
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.
Zacks
Insmed to Present at September 2026 Investor Conferences
Insmed to Present at September 2026 Investor Conferences Insmed to Present at September 2026 Investor Conferences PR Newswire BRIDGEWATER, N.J., Aug. 26, 2026 BRIDGEWATER, N.J., Aug. 26, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company...
PR Newswire
BRINSUPRI (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
BRINSUPRI (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease BRINSUPRI (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients...
PR Newswire
Top Analyst Reports for Visa, Lam Research & Caterpillar
Visa's payments growth, Lam Research's AI-driven demand and Caterpillar's broad market momentum headline today's top analyst reports.
Zacks
Insmed (INSM) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
$1000 Invested In Insmed 5 Years Ago Would Be Worth This Much Today
Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 29.76% on an annualized basis producing an average annual return of 41.43%. Currently, Insmed has a market capitalization of $28.82 billion.read more...
Benzinga

Advertisement|Remove ads.